The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

I t’s hard to argue that the introduction of drugs like Ozempic has been anything short of revolutionary for people looking ...

More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The lawsuits come amid several recent studies showing a link between vision complications and people taking drugs containing semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

(CNN) – The crackdown on off-brand weight loss and diabetes treatment drugs is about to take effect, meaning supplies for the treatments are likely to tighten. A federal deadline to halt sales of the ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.